Nextcure publishes non-clinical data defining the mechanism of action for nc525, a novel lair-1 antibody for aml

Beltsville, md., nov. 15, 2023 (globe newswire) -- nextcure, inc. (nasdaq: nxtc), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of a manuscript titled “lair-1 agonism as a therapy for acute myeloid leukemia” in the journal of clinical investigation. the data demonstrate that nc525 induces cell death in acute myeloid leukemia (aml) blast cells and leukemic stem cells (lscs) through leukocyte-associated immunoglobin-like receptor-1 (lair-1) agonism by driving a unique apoptotic signaling pathway.
NXTC Ratings Summary
NXTC Quant Ranking